Gerresheimer Glas
VC Fund
Düsseldorf, Germany
Gerresheimer Glas is a VC fund in Düsseldorf focused on Health Care and Medical Device. Gerresheimer is a leading global partner to the pharma and healthcare industry. With our specialty glass and plastic products, we contribute to health and well-being. We have worldwide operations and about 10,000 employees manufacture our products in local markets, close to our customers. With our plants in Europe, North America, South America, andAsia, we generate revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: Insulin pens, inhalers, refillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Gerresheimer Glas invests in
Stages Gerresheimer Glas invests in
Countries Gerresheimer Glas invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Health Care 1 (100%)
- Medical Device 1 (100%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bernd Metzner
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Daniel Diezi
Vice President Digitalization & New Business Models
|
Vice President Digitalization & New Business Models | Total investments: 0 | Find email | |
Dietmar Siemssen
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Adamant Health
|
Adamant Health’s unique technology to analyse Parkinson’s disease symptoms is based on over 15 years of academic research at the University of Eastern Finland. With the technology, clinicians have several days detailed visibility to the patient’s symptoms and is able to optimise the treatment accordingly. Pharma companies benefit from the objectiveand long-term RW data in their clinical and post market studies and can utilise it as complementary diagnostics tool for personalised medication. | $2.3M / Seed / Jun 13, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gerresheimer Glas invest in?
Gerresheimer Glas invests primarily in Health Care and Medical Device startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gerresheimer Glas?
Public channels for Gerresheimer Glas include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Gerresheimer Glas?
The team at Gerresheimer Glas includes Bernd Metzner (Chief Financial Officer), Daniel Diezi (Vice President Digitalization & New Business Models) and Dietmar Siemssen (Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
